On Monday, Black Diamond Therapeutics Inc (NASDAQ: BDTX) was 3.46% up from the session before settling in for the closing price of $2.89. A 52-week range for BDTX has been $1.62 – $7.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at 23.44%. With a float of $43.06 million, this company’s outstanding shares have now reached $51.65 million.
Let’s determine the extent of company efficiency that accounts for 54 employees. In terms of profitability, gross margin is 77.91%, operating margin of -1782.65%, and the pretax margin is -1645.87%.
Black Diamond Therapeutics Inc (BDTX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Black Diamond Therapeutics Inc stocks. The insider ownership of Black Diamond Therapeutics Inc is 23.80%, while institutional ownership is 72.04%. The most recent insider transaction that took place on Aug 28 ’24, was worth 1,400,556. In this transaction 10% Owner of this company sold 221,600 shares at a rate of $6.32, taking the stock ownership to the 3,726,341 shares. Before that another transaction happened on Jul 31 ’24, when Company’s Former Employer proposed sale 50,000 for $6.20, making the entire transaction worth $310,000.
Black Diamond Therapeutics Inc (BDTX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 23.44% per share during the next fiscal year.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Trading Performance Indicators
You can see what Black Diamond Therapeutics Inc (BDTX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.54, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -1.35 in one year’s time.
Technical Analysis of Black Diamond Therapeutics Inc (BDTX)
Looking closely at Black Diamond Therapeutics Inc (NASDAQ: BDTX), its last 5-days average volume was 0.7 million, which is a drop from its year-to-date volume of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 24.07%. Additionally, its Average True Range was 0.25.
During the past 100 days, Black Diamond Therapeutics Inc’s (BDTX) raw stochastic average was set at 6.35%, which indicates a significant decrease from 33.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.67% in the past 14 days, which was lower than the 80.30% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.34, while its 200-day Moving Average is $4.89. However, in the short run, Black Diamond Therapeutics Inc’s stock first resistance to watch stands at $3.11. Second resistance stands at $3.22. The third major resistance level sits at $3.34. If the price goes on to break the first support level at $2.88, it is likely to go to the next support level at $2.76. Should the price break the second support level, the third support level stands at $2.65.
Black Diamond Therapeutics Inc (NASDAQ: BDTX) Key Stats
There are 56,505K outstanding shares of the company, which has a market capitalization of 178.20 million. As of now, sales total 0 K while income totals -82,440 K. Its latest quarter income was 0 K while its last quarter net income were -19,910 K.
